Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer

被引：4

作者：

Livi, L. ^{[1
]}

Meattini, I. ^{[1
]}

Cardillo, C. De Luca ^{[1
]}

Scotti, V. ^{[1
]}

Agresti, B. ^{[1
]}

Franzese, C. ^{[1
]}

Sanchez, L. ^{[2
]}

Nori, J. ^{[3
]}

Bertocci, S. ^{[1
]}

Cassani, S. ^{[1
]}

Bianchi, S. ^{[4
]}

Cataliotti, L. ^{[2
]}

Biti, G. ^{[1
]}

机构：

[1] Univ Florence, Dept Radiat Oncol, I-50134 Florence, Italy

[2] Univ Florence, Dept Surg, I-50134 Florence, Italy

[3] Univ Florence, Diagnost Senol Unit, I-50134 Florence, Italy

[4] Univ Florence, Dept Pathol, I-50134 Florence, Italy

来源：

JOURNAL OF CHEMOTHERAPY | 2011年 / 23卷 / 01期

关键词：

Breast cancer; anthracycline; adjuvant chemotherapy; cardiac safety; docetaxel; COLONY-STIMULATING FACTORS; FEBRILE NEUTROPENIA; METAANALYSIS; TAC; RECOMMENDATIONS; UPDATE; LIFE;

D O I：

10.1179/joc.2011.23.1.36

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evaluated the feasibility and incidence of hematological toxicity in a series of 39 breast cancer patients treated at our Institute with doxorubicin plus cyclophosphamide (AC) followed by docetaxel, using prophylactic G-CSF (Pegfilgrastim). We prescribed G-CSF as secondary prophylaxis during the AC regimen and as primary prophylaxis during treatment with docetaxel. For the AC treatment, we recorded 6 cases of grade III (15.3%) and one case of grade IV (2.5%) neutropenia; we found one case of Grade IV anemia. For the docetaxel regimen, we registered one case of Grade IV (2.5%) neutropenia and three cases of Grade III leukopoenia without neutropenia. No patients experienced cardiac symptoms or baseline LVEF rate decrease. All patients concluded the programmed chemotherapy. Our experience shows the safety of docetaxel in combination with anthracyclines and the efficacy of prophylaxis with G-CSF in breast cancer adjuvant chemotherapy.

引用

页码：36 / 39

页数：4

共 23 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer [J].

Brain, EGC ;

Bachelot, T ;

Serin, D ;

Kirscher, S ;

Graic, Y ;

Eymard, JC ;

Extra, JM ;

Combe, M ;

Fourme, E ;

Noguès, C ;

Rouëssé, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (19) :2367-2371

[3]

Clarke M, 2008, LANCET, V371, P29, DOI 10.1016/S0140-6736(08)60069-0

[4] Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials [J].

De Laurentiis, Michele ;

Cancello, Giuseppe ;

D'Agostino, Diego ;

Giuliano, Mario ;

Giordano, Antonio ;

Montagna, Emilia ;

Lauria, Rossella ;

Forestieri, Valeria ;

Esposito, Angela ;

Silvestro, Lucrezia ;

Pennacchio, Roberta ;

Criscitiello, Carmen ;

Montanino, Agnese ;

Limite, Gennaro ;

Bianco, Angelo Raffaele ;

De Placido, Sabino .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :44-53

[5]

DILEO A, 2009, CANC RES S, V69

[6] Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial [J].

Ellis, Paul ;

Barrett-Lee, Peter ;

Johnson, Lindsay ;

Cameron, David ;

Wardley, Andrew ;

O'Reilly, Susan ;

Verrill, Mark ;

Smith, Ian ;

Yarnold, John ;

Coleman, Robert ;

Earl, Helena ;

Canney, Peter ;

Twelves, Chris ;

Poole, Christopher ;

Bloomfield, David ;

Hopwood, Penelope ;

Johnston, Stephen ;

Dowsett, Mitchell ;

Bartlett, John M. S. ;

Ellis, Ian ;

Peckitt, Clare ;

Hall, Emma ;

Bliss, Judith M. .

LANCET, 2009, 373 (9676) :1681-1692

[7] Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel:: Breast International Group 02-98 randomized trial [J].

Francis, Prudence ;

Crown, John ;

Di Leo, Angelo ;

Buyse, Marc ;

Balil, Ana ;

Andersson, Michael ;

Nordenskjold, Bo ;

Lang, Istvan ;

Jakesz, Raimund ;

Vorobiof, Daniel ;

Gutierrez, Jorge ;

van Hazel, Guy ;

Dolci, Stella ;

Jamin, Sophie ;

Bendahmane, Belguendouz ;

Gelber, Richard D. ;

Goldhirsch, Aron ;

Castiglione-Gertsch, Monica ;

Piccart-Gebhart, Martine .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (02) :121-133

[8] The economics of febrile neutropenia: Implications for the use of colony-stimulating factors [J].

Lyman, GH ;

Kuderer, N ;

Greene, J ;

Balducci, L .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) :1857-1864

[9] Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC):: impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen [J].

Martin, M. ;

Lluch, A. ;

Segui, M. A. ;

Ruiz, A. ;

Ramos, M. ;

Adrover, E. ;

Roriguez-Lescure, A. ;

Grosse, R. ;

Calvo, L. ;

Fernandez-Chacon, C. ;

Roset, M. ;

Anton, A. ;

Isla, D. ;

Martinez del Prado, P. ;

Iglesias, L. ;

Zaluski, J. ;

Arcusa, A. ;

Loez-Vega, J. M. ;

Munoz, M. ;

Mel, J. R. .

ANNALS OF ONCOLOGY, 2006, 17 (08) :1205-1212

[10] Adjuvant docetaxel for node-positive breast cancer [J].

Martin, M ;

Pienkowski, T ;

Mackey, J ;

Pawlicki, M ;

Guastalla, JP ;

Weaver, C ;

Tomiak, E ;

Al-Tweigeri, T ;

Chap, L ;

Juhos, E ;

Guevin, R ;

Howell, A ;

Fornander, T ;

Hainsworth, J ;

Coleman, R ;

Vinholes, J ;

Modiano, M ;

Pinter, T ;

Tang, SC ;

Colwell, B ;

Prady, C ;

Provencher, L ;

Walde, D ;

Rodriguez-Lescure, A ;

Hugh, J ;

Loret, C ;

Rupin, M ;

Blitz, S ;

Jacobs, P ;

Murawsky, M ;

Riva, A ;

Vogel, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2302-2313

← 1 2 3 →